

6 References

1. Michalik, L.; Auwerx, J.; Berger, J. P.; Chatterjee, V. K.; Glass, C. K.; Gonzalez, F. J.; Grimaldi, P. A.; Kadowaki, T.; Lazar, M. A.; O'Rahilly, S.; Palmer, C. N.; Plutzky, J.; Reddy, J. K.; Spiegelman, B. M.; Staels, B.; Wahli, W., International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. *Pharmacol Rev* **2006**, 58, (4), 726-41.
2. Desvergne, B.; Michalik, L.; Wahli, W., Be fit or be sick: peroxisome proliferator-activated receptors are down the road. *Mol Endocrinol* **2004**, 18, (6), 1321-32.
3. Shearer, B. G.; Hoekstra, W. J., Recent advances in peroxisome proliferator-activated receptor science. *Curr Med Chem* **2003**, 10, (4), 267-80.
4. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R., The PPARs: from orphan receptors to drug discovery. *J Med Chem* **2000**, 43, (4), 527-50.
5. Berger, J.; Moller, D. E., The mechanisms of action of PPARs. *Annu Rev Med* **2002**, 53, 409-35.
6. Feige, J. N.; Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W., From molecular action to physiological outputs: peroxisome proliferator-activated receptors

- are nuclear receptors at the crossroads of key cellular functions. *Prog Lipid Res* **2006**, 45, (2), 120-59.
7. Thorp, J. M.; Waring, W. S., Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. *Nature* **1962**, 194, 948-9.
 8. Hellman, L.; Zumoff, B.; Kessler, G.; Kara, E.; Rubin, I. L.; Rosenfeld, R. S., Reduction of Serum Cholesterol and Lipids by Ethyl Chlorophenoxyisobutyrate. *J Atheroscler Res* **1963**, 3, 454-66.
 9. Kawamatsu, Y.; Saraie, T.; Imamiya, E.; Nishikawa, K.; Hamuro, Y., Studies on antihyperlipidemic agents. I. Synthesis and hypolipidemic activities of phenoxyphenyl alkanoic acid derivatives. *Arzneimittelforschung* **1980**, 30, (3), 454-9.
 10. Fujita, T.; Sugiyama, Y.; Taketomi, S.; Sohda, T.; Kawamatsu, Y.; Iwatsuka, H.; Suzuoki, Z., Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. *Diabetes* **1983**, 32, (9), 804-10.
 11. Fujiwara, T.; Yoshioka, S.; Yoshioka, T.; Ushiyama, I.; Horikoshi, H., Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. *Diabetes* **1988**, 37, (11), 1549-58.
 12. Sohda, T.; Momose, Y.; Meguro, K.; Kawamatsu, Y.; Sugiyama, Y.; Ikeda, H., Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. *Arzneimittelforschung* **1990**, 40, (1), 37-42.
 13. Oakes, N. D.; Kennedy, C. J.; Jenkins, A. B.; Laybutt, D. R.; Chisholm, D. J.; Kraegen, E. W., A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. *Diabetes* **1994**, 43, (10), 1203-10.
 14. Reddy, J. K.; Goel, S. K.; Nemali, M. R.; Carrino, J. J.; Laffler, T. G.; Reddy, M. K.; Sperbeck, S. J.; Osumi, T.; Hashimoto, T.; Lalwani, N. D.; et al., Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. *Proc Natl Acad Sci U S A* **1986**, 83, (6), 1747-51.
 15. Staels, B.; van Tol, A.; Verhoeven, G.; Auwerx, J., Apolipoprotein A-IV messenger ribonucleic acid abundance is regulated in a tissue-specific manner. *Endocrinology* **1990**, 126, (4), 2153-63.

16. Issemann, I.; Green, S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. *Nature* **1990**, 347, (6294), 645-50.
17. Tontonoz, P.; Hu, E.; Spiegelman, B. M., Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. *Cell* **1994**, 79, (7), 1147-56.
18. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). *J Biol Chem* **1995**, 270, (22), 12953-6.
19. Kota, B. P.; Huang, T. H.; Roufogalis, B. D., An overview on biological mechanisms of PPARs. *Pharmacol Res* **2005**, 51, (2), 85-94.
20. Kliewer, S. A.; Umesono, K.; Noonan, D. J.; Heyman, R. A.; Evans, R. M., Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. *Nature* **1992**, 358, (6389), 771-4.
21. Zoete, V.; Grosdidier, A.; Michielin, O., Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. *Biochim Biophys Acta* **2007**, 1771, (8), 915-25.
22. Sher, T.; Yi, H. F.; McBride, O. W.; Gonzalez, F. J., cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. *Biochemistry* **1993**, 32, (21), 5598-604.
23. Kersten, S.; Wahli, W., Peroxisome proliferator activated receptor agonists. *EXS* **2000**, 89, 141-51.
24. Palmer, C. N.; Hsu, M. H.; Griffin, K. J.; Raucy, J. L.; Johnson, E. F., Peroxisome proliferator activated receptor-alpha expression in human liver. *Mol Pharmacol* **1998**, 53, (1), 14-22.
25. Lambe, K. G.; Woodyatt, N. J.; Macdonald, N.; Chevalier, S.; Roberts, R. A., Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. *Toxicol Lett* **1999**, 110, (1-2), 119-27.
26. Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G.; Wahli, W., Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. *Cell* **1992**, 68, (5), 879-87.

27. Schmidt, A.; Endo, N.; Rutledge, S. J.; Vogel, R.; Shinar, D.; Rodan, G. A., Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. *Mol Endocrinol* **1992**, 6, (10), 1634-41.
28. Chen, F.; Law, S. W.; O'Malley, B. W., Identification of two mPPAR related receptors and evidence for the existence of five subfamily members. *Biochem Biophys Res Commun* **1993**, 196, (2), 671-7.
29. Auboeuf, D.; Rieusset, J.; Fajas, L.; Vallier, P.; Frering, V.; Riou, J. P.; Staels, B.; Auwerx, J.; Laville, M.; Vidal, H., Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. *Diabetes* **1997**, 46, (8), 1319-27.
30. Feldman, P. L.; Lambert, M. H.; Henke, B. R., PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? *Curr Top Med Chem* **2008**, 8, (9), 728-49.
31. E, K., Studien uber das Hypertonie-Hyperglyka "mie-Hyperurika" miesyndrom. *Zentralbl Inn Med* **1923**, 44, 105-127.
32. J, V., La differentiation sexuelle, facteur determinant des formes de l'obesite. *Presse Med* **1947**, 53, 339-340.
33. Reaven, G. M., Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* **1988**, 37, (12), 1595-607.
34. Kaplan, N. M., The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. *Arch Intern Med* **1989**, 149, (7), 1514-20.
35. Haffner, S. M.; Valdez, R. A.; Hazuda, H. P.; Mitchell, B. D.; Morales, P. A.; Stern, M. P., Prospective analysis of the insulin-resistance syndrome (syndrome X). *Diabetes* **1992**, 41, (6), 715-22.
36. A, I. J.; Jeannin, E.; Wahli, W.; Desvergne, B., Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. *J Biol Chem* **1997**, 272, (32), 20108-17.
37. Juge-Aubry, C.; Pernin, A.; Favez, T.; Burger, A. G.; Wahli, W.; Meier, C. A.; Desvergne, B., DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response

- elements. Importance of the 5'-flanking region. *J Biol Chem* **1997**, 272, (40), 25252-9.
38. Lemberger, T.; Desvergne, B.; Wahli, W., Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. *Annu Rev Cell Dev Biol* **1996**, 12, 335-63.
 39. Chen, J. D.; Evans, R. M., A transcriptional co-repressor that interacts with nuclear hormone receptors. *Nature* **1995**, 377, (6548), 454-7.
 40. Horlein, A. J.; Naar, A. M.; Heinzl, T.; Torchia, J.; Gloss, B.; Kurokawa, R.; Ryan, A.; Kamei, Y.; Soderstrom, M.; Glass, C. K.; et al., Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. *Nature* **1995**, 377, (6548), 397-404.
 41. Xu, L.; Glass, C. K.; Rosenfeld, M. G., Coactivator and corepressor complexes in nuclear receptor function. *Curr Opin Genet Dev* **1999**, 9, (2), 140-7.
 42. Zhu, Y.; Qi, C.; Calandra, C.; Rao, M. S.; Reddy, J. K., Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. *Gene Expr* **1996**, 6, (3), 185-95.
 43. Zhu, Y.; Qi, C.; Jain, S.; Rao, M. S.; Reddy, J. K., Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. *J Biol Chem* **1997**, 272, (41), 25500-6.
 44. Reddy, J. K., Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. *Am J Physiol Gastrointest Liver Physiol* **2001**, 281, (6), G1333-9.
 45. Guan, Y.; Breyer, M. D., Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. *Kidney Int* **2001**, 60, (1), 14-30.
 46. Leone, T. C.; Weinheimer, C. J.; Kelly, D. P., A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. *Proc Natl Acad Sci U S A* **1999**, 96, (13), 7473-8.
 47. Neve, B. P.; Fruchart, J. C.; Staels, B., Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. *Biochem Pharmacol* **2000**, 60, (8), 1245-50.
 48. Fruchart, J. C., Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. *Am J Cardiol* **2001**, 88, (12A), 24N-29N.

49. Motojima, K.; Passilly, P.; Peters, J. M.; Gonzalez, F. J.; Latruffe, N., Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. *J Biol Chem* **1998**, 273, (27), 16710-4.
50. Seedorf, U.; Assmann, G., The role of PPAR alpha in obesity. *Nutr Metab Cardiovasc Dis* **2001**, 11, (3), 189-94.
51. Costet, P.; Legendre, C.; More, J.; Edgar, A.; Galtier, P.; Pineau, T., Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. *J Biol Chem* **1998**, 273, (45), 29577-85.
52. Koh, E. H.; Kim, M. S.; Park, J. Y.; Kim, H. S.; Youn, J. Y.; Park, H. S.; Youn, J. H.; Lee, K. U., Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. *Diabetes* **2003**, 52, (9), 2331-7.
53. Panz, V. R.; Wing, J. R.; Raal, F. J.; Kedda, M. A.; Joffe, B. I., Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis? *Clin Endocrinol (Oxf)* **1997**, 46, (3), 365-8.
54. Marx, N.; Sukhova, G. K.; Collins, T.; Libby, P.; Plutzky, J., PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. *Circulation* **1999**, 99, (24), 3125-31.
55. Diep, Q. N.; Touyz, R. M.; Schiffrin, E. L., Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. *Hypertension* **2000**, 36, (5), 851-5.
56. Kintscher, U.; Lyon, C.; Wakino, S.; Bruemmer, D.; Feng, X.; Goetze, S.; Graf, K.; Moustakas, A.; Staels, B.; Fleck, E.; Hsueh, W. A.; Law, R. E., PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. *Circ Res* **2002**, 91, (11), e35-44.
57. Johnson, E. F.; Palmer, C. N.; Griffin, K. J.; Hsu, M. H., Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. *FASEB J* **1996**, 10, (11), 1241-8.
58. Duez, H.; Chao, Y. S.; Hernandez, M.; Torpier, G.; Poulain, P.; Mundt, S.; Mallat, Z.; Teissier, E.; Burton, C. A.; Tedgui, A.; Fruchart, J. C.; Fievet, C.; Wright, S. D.; Staels, B., Reduction of atherosclerosis by the peroxisome proliferator-

- activated receptor alpha agonist fenofibrate in mice. *J Biol Chem* **2002**, 277, (50), 48051-7.
59. Fajas, L.; Debril, M. B.; Auwerx, J., Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. *J Mol Endocrinol* **2001**, 27, (1), 1-9.
 60. Barroso, I.; Gurnell, M.; Crowley, V. E.; Agostini, M.; Schwabe, J. W.; Soos, M. A.; Maslen, G. L.; Williams, T. D.; Lewis, H.; Schafer, A. J.; Chatterjee, V. K.; O'Rahilly, S., Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. *Nature* **1999**, 402, (6764), 880-3.
 61. Steppan, C. M.; Bailey, S. T.; Bhat, S.; Brown, E. J.; Banerjee, R. R.; Wright, C. M.; Patel, H. R.; Ahima, R. S.; Lazar, M. A., The hormone resistin links obesity to diabetes. *Nature* **2001**, 409, (6818), 307-12.
 62. Lee, C. H.; Olson, P.; Evans, R. M., Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. *Endocrinology* **2003**, 144, (6), 2201-7.
 63. Savage, D. B.; Tan, G. D.; Acerini, C. L.; Jebb, S. A.; Agostini, M.; Gurnell, M.; Williams, R. L.; Umpleby, A. M.; Thomas, E. L.; Bell, J. D.; Dixon, A. K.; Dunne, F.; Boiani, R.; Cinti, S.; Vidal-Puig, A.; Karpe, F.; Chatterjee, V. K.; O'Rahilly, S., Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. *Diabetes* **2003**, 52, (4), 910-7.
 64. Komers, R.; Vrana, A., Thiazolidinediones--tools for the research of metabolic syndrome X. *Physiol Res* **1998**, 47, (4), 215-25.
 65. Freed, M. I.; Ratner, R.; Marcovina, S. M.; Kreider, M. M.; Biswas, N.; Cohen, B. R.; Brunzell, J. D., Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. *Am J Cardiol* **2002**, 90, (9), 947-52.
 66. Ogihara, T.; Rakugi, H.; Ikegami, H.; Mikami, H.; Masuo, K., Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. *Am J Hypertens* **1995**, 8, (3), 316-20.
 67. Saku, K.; Zhang, B.; Ohta, T.; Arakawa, K., Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. *Am J Hypertens* **1997**, 10, (9 Pt 1), 1027-33.

68. Ryan, M. J.; Didion, S. P.; Mathur, S.; Faraci, F. M.; Sigmund, C. D., PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. *Hypertension* **2004**, 43, (3), 661-6.
69. Ghazzi, M. N.; Perez, J. E.; Antonucci, T. K.; Driscoll, J. H.; Huang, S. M.; Faja, B. W.; Whitcomb, R. W., Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. *Diabetes* **1997**, 46, (3), 433-9.
70. Peters, J. M.; Lee, S. S.; Li, W.; Ward, J. M.; Gavrilova, O.; Everett, C.; Reitman, M. L.; Hudson, L. D.; Gonzalez, F. J., Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). *Mol Cell Biol* **2000**, 20, (14), 5119-28.
71. Barak, Y.; Liao, D.; He, W.; Ong, E. S.; Nelson, M. C.; Olefsky, J. M.; Boland, R.; Evans, R. M., Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. *Proc Natl Acad Sci U S A* **2002**, 99, (1), 303-8.
72. Wang, Y. X.; Lee, C. H.; Tiep, S.; Yu, R. T.; Ham, J.; Kang, H.; Evans, R. M., Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. *Cell* **2003**, 113, (2), 159-70.
73. Leibowitz, M. D.; Fievet, C.; Hennuyer, N.; Peinado-Onsurbe, J.; Duez, H.; Bergera, J.; Cullinan, C. A.; Sparrow, C. P.; Baffic, J.; Berger, G. D.; Santini, C.; Marquis, R. W.; Tolman, R. L.; Smith, R. G.; Moller, D. E.; Auwerx, J., Activation of PPARdelta alters lipid metabolism in db/db mice. *FEBS Lett* **2000**, 473, (3), 333-6.
74. Oliver, W. R., Jr.; Shenk, J. L.; Snaith, M. R.; Russell, C. S.; Plunket, K. D.; Bodkin, N. L.; Lewis, M. C.; Winegar, D. A.; Sznaidman, M. L.; Lambert, M. H.; Xu, H. E.; Sternbach, D. D.; Kliewer, S. A.; Hansen, B. C.; Willson, T. M., A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. *Proc Natl Acad Sci U S A* **2001**, 98, (9), 5306-11.
75. Tanaka, T.; Yamamoto, J.; Iwasaki, S.; Asaba, H.; Hamura, H.; Ikeda, Y.; Watanabe, M.; Magoori, K.; Ioka, R. X.; Tachibana, K.; Watanabe, Y.; Uchiyama, Y.; Sumi, K.; Iguchi, H.; Ito, S.; Doi, T.; Hamakubo, T.; Naito, M.; Auwerx, J.; Yanagisawa, M.; Kodama, T.; Sakai, J., Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. *Proc Natl Acad Sci U S A* **2003**, 100, (26), 15924-9.
76. Medzhitov, R., Origin and physiological roles of inflammation. *Nature* **2008**, 454, (7203), 428-35.

77. Devchand, P. R.; Keller, H.; Peters, J. M.; Vazquez, M.; Gonzalez, F. J.; Wahli, W., The PPARalpha-leukotriene B4 pathway to inflammation control. *Nature* **1996**, 384, (6604), 39-43.
78. Kobayashi, Y.; Ueki, S.; Mahemuti, G.; Chiba, T.; Oyamada, H.; Saito, N.; Kanda, A.; Kayaba, H.; Chihara, J., Physiological levels of 15-deoxy-Delta12,14-prostaglandin J2 prime eotaxin-induced chemotaxis on human eosinophils through peroxisome proliferator-activated receptor-gamma ligation. *J Immunol* **2005**, 175, (9), 5744-50.
79. Cabrero, A.; Laguna, J. C.; Vazquez, M., Peroxisome proliferator-activated receptors and the control of inflammation. *Curr Drug Targets Inflamm Allergy* **2002**, 1, (3), 243-8.
80. Ghosh, S.; May, M. J.; Kopp, E. B., NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. *Annu Rev Immunol* **1998**, 16, 225-60.
81. Heyninck, K.; Wullaert, A.; Beyaert, R., Nuclear factor-kappa B plays a central role in tumour necrosis factor-mediated liver disease. *Biochem Pharmacol* **2003**, 66, (8), 1409-15.
82. Delerive, P.; De Bosscher, K.; Besnard, S.; Vanden Berghe, W.; Peters, J. M.; Gonzalez, F. J.; Fruchart, J. C.; Tedgui, A.; Haegeman, G.; Staels, B., Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. *J Biol Chem* **1999**, 274, (45), 32048-54.
83. Delerive, P.; De Bosscher, K.; Vanden Berghe, W.; Fruchart, J. C.; Haegeman, G.; Staels, B., DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. *Mol Endocrinol* **2002**, 16, (5), 1029-39.
84. Pascual, G.; Fong, A. L.; Ogawa, S.; Gamliel, A.; Li, A. C.; Perissi, V.; Rose, D. W.; Willson, T. M.; Rosenfeld, M. G.; Glass, C. K., A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. *Nature* **2005**, 437, (7059), 759-63.
85. Lee, C. H.; Chawla, A.; Urbiztondo, N.; Liao, D.; Boisvert, W. A.; Evans, R. M.; Curtiss, L. K., Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. *Science* **2003**, 302, (5644), 453-7.
86. Barish, G. D.; Atkins, A. R.; Downes, M.; Olson, P.; Chong, L. W.; Nelson, M.; Zou, Y.; Hwang, H.; Kang, H.; Curtiss, L.; Evans, R. M.; Lee, C. H., PPARdelta regulates

- multiple proinflammatory pathways to suppress atherosclerosis. *Proc Natl Acad Sci U S A* **2008**, 105, (11), 4271-6.
87. Ricote, M.; Li, A. C.; Willson, T. M.; Kelly, C. J.; Glass, C. K., The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature* **1998**, 391, (6662), 79-82.
 88. Takata, Y.; Liu, J.; Yin, F.; Collins, A. R.; Lyon, C. J.; Lee, C. H.; Atkins, A. R.; Downes, M.; Barish, G. D.; Evans, R. M.; Hsueh, W. A.; Tangirala, R. K., PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. *Proc Natl Acad Sci U S A* **2008**, 105, (11), 4277-82.
 89. Varga, T.; Czimmerer, Z.; Nagy, L., PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. *Biochim Biophys Acta* **2011**, 1812, (8), 1007-22.
 90. Tan, N. S.; Michalik, L.; Di-Poi, N.; Desvergne, B.; Wahli, W., Critical roles of the nuclear receptor PPARbeta (peroxisome-proliferator-activated receptor beta) in skin wound healing. *Biochem Soc Trans* **2004**, 32, (Pt 1), 97-102.
 91. Pineda Torra, I.; Gervois, P.; Staels, B., Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. *Curr Opin Lipidol* **1999**, 10, (2), 151-9.
 92. Brown, P. J.; Winegar, D. A.; Plunket, K. D.; Moore, L. B.; Lewis, M. C.; Wilson, J. G.; Sundseth, S. S.; Koble, C. S.; Wu, Z.; Chapman, J. M.; Lehmann, J. M.; Kliewer, S. A.; Willson, T. M., A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. *J Med Chem* **1999**, 42, (19), 3785-8.
 93. Xu, Y.; Mayhugh, D.; Saeed, A.; Wang, X.; Thompson, R. C.; Dominianni, S. J.; Kauffman, R. F.; Singh, J.; Bean, J. S.; Bensh, W. R.; Barr, R. J.; Osborne, J.; Montrose-Rafizadeh, C.; Zink, R. W.; Yumibe, N. P.; Huang, N.; Luffer-Atlas, D.; Rungta, D.; Maise, D. E.; Mantlo, N. B., Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. *J Med Chem* **2003**, 46, (24), 5121-4.
 94. Kuwabara, K.; Murakami, K.; Todo, M.; Aoki, T.; Asaki, T.; Murai, M.; Yano, J., A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane -r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice. *J Pharmacol Exp Ther* **2004**, 309, (3), 970-7.

95. Schafer, S. A.; Hansen, B. C.; Volkl, A.; Fahimi, H. D.; Pill, J., Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR) α activator, in non-human primates. *Biochem Pharmacol* **2004**, 68, (2), 239-51.
96. Martin, G.; Schoonjans, K.; Staels, B.; Auwerx, J., PPAR γ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. *Atherosclerosis* **1998**, 137 Suppl, S75-80.
97. Rosen, E. D.; Spiegelman, B. M., PPAR γ : a nuclear regulator of metabolism, differentiation, and cell growth. *J Biol Chem* **2001**, 276, (41), 37731-4.
98. Kawamatsu, Y.; Asakawa, H.; Saraie, T.; Mizuno, K.; Imamiya, E.; Nishikawa, K.; Hamuro, Y., Studies on antihyperlipidemic agents. III. Synthesis and biological activities of 2-chloro-3-arylpropionic acids containing a quarternary carbon atom. *Arzneimittelforschung* **1980**, 30, (5), 751-8.
99. Sohda, T.; Mizuno, K.; Tawada, H.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y., Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2-phenylpropoxy)-benzyl]thiazolidine-2,4-dione (AL-321) and related compounds. *Chem Pharm Bull (Tokyo)* **1982**, 30, (10), 3563-73.
100. Chang, A. Y.; Wyse, B. M.; Gilchrist, B. J.; Peterson, T.; Diani, A. R., Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. *Diabetes* **1983**, 32, (9), 830-8.
101. Sohda, T.; Kawamatsu, Y.; Fujita, T.; Meguro, K.; Ikeda, H., [Discovery and development of a new insulin sensitizing agent, pioglitazone]. *Yakugaku Zasshi* **2002**, 122, (11), 909-18.
102. Sohda, T.; Mizuno, K.; Momose, Y.; Ikeda, H.; Fujita, T.; Meguro, K., Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. *J Med Chem* **1992**, 35, (14), 2617-26.
103. Azen, S. P.; Peters, R. K.; Berkowitz, K.; Kjos, S.; Xiang, A.; Buchanan, T. A., TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. *Control Clin Trials* **1998**, 19, (2), 217-31.
104. Iwamoto, Y.; Kosaka, K.; Kuzuya, T.; Akanuma, Y.; Shigeta, Y.; Kaneko, T., Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. *Diabetes Care* **1996**, 19, (2), 151-6.

105. Clark, D. A.; Goldstein, S. W.; Volkmann, R. A.; Eggler, J. F.; Holland, G. F.; Hulin, B.; Stevenson, R. W.; Kreutter, D. K.; Gibbs, E. M.; Krupp, M. N.; et al., Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents. *J Med Chem* **1991**, 34, (1), 319-25.
106. Gale, E. A., Lessons from the glitazones: a story of drug development. *Lancet* **2001**, 357, (9271), 1870-5.
107. Rosenblatt, S.; Miskin, B.; Glazer, N. B.; Prince, M. J.; Robertson, K. E., The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. *Coron Artery Dis* **2001**, 12, (5), 413-23.
108. Aronoff, S.; Rosenblatt, S.; Braithwaite, S.; Egan, J. W.; Mathisen, A. L.; Schneider, R. L., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. *Diabetes Care* **2000**, 23, (11), 1605-11.
109. Phillips, L. S.; Grunberger, G.; Miller, E.; Patwardhan, R.; Rappaport, E. B.; Salzman, A., Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. *Diabetes Care* **2001**, 24, (2), 308-15.
110. Wagstaff, A. J.; Goa, K. L., Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. *Drugs* **2002**, 62, (12), 1805-37.
111. Lebovitz, H. E.; Dole, J. F.; Patwardhan, R.; Rappaport, E. B.; Freed, M. I., Rosiglitazone monotherapy is effective in patients with type 2 diabetes. *J Clin Endocrinol Metab* **2001**, 86, (1), 280-8.
112. Schimke, K.; Davis, T. M., Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes. *Curr Opin Investig Drugs* **2007**, 8, (4), 338-44.
113. Larsen, P. J.; Lykkegaard, K.; Larsen, L. K.; Fleckner, J.; Sauerberg, P.; Wassermann, K.; Wulff, E. M., Dissociation of antihyperglycaemic and adverse effects of partial peroxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. *Eur J Pharmacol* **2008**, 596, (1-3), 173-9.
114. Rybczynski, P. J.; Zeck, R. E.; Dudash, J., Jr.; Combs, D. W.; Burris, T. P.; Yang, M.; Osborne, M. C.; Chen, X.; Demarest, K. T., Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model. *J Med Chem* **2004**, 47, (1), 196-209.
115. Henke, B. R.; Blanchard, S. G.; Brackeen, M. F.; Brown, K. K.; Cobb, J. E.; Collins, J. L.; Harrington, W. W., Jr.; Hashim, M. A.; Hull-Ryde, E. A.; Kaldor, I.; Klierer, S.

- A.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J. M.; Lenhard, J. M.; Orband-Miller, L. A.; Miller, J. F.; Mook, R. A., Jr.; Noble, S. A.; Oliver, W., Jr.; Parks, D. J.; Plunket, K. D.; Szewczyk, J. R.; Willson, T. M., N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. *J Med Chem* **1998**, 41, (25), 5020-36.
116. Devasthale, P. V.; Chen, S.; Jeon, Y.; Qu, F.; Shao, C.; Wang, W.; Zhang, H.; Cap, M.; Farrelly, D.; Golla, R.; Grover, G.; Harrity, T.; Ma, Z.; Moore, L.; Ren, J.; Seethala, R.; Cheng, L.; Sleph, P.; Sun, W.; Tieman, A.; Wetterau, J. R.; Doweyko, A.; Chandrasena, G.; Chang, S. Y.; Humphreys, W. G.; Sasseville, V. G.; Biller, S. A.; Ryono, D. E.; Selan, F.; Hariharan, N.; Cheng, P. T., Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. *J Med Chem* **2005**, 48, (6), 2248-50.
117. Hegarty, B. D.; Furler, S. M.; Oakes, N. D.; Kraegen, E. W.; Cooney, G. J., Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar. *Endocrinology* **2004**, 145, (7), 3158-64.
118. Lohray, B. B.; Lohray, V. B.; Bajji, A. C.; Kalchar, S.; Poondra, R. R.; Padakanti, S.; Chakrabarti, R.; Vikramadithyan, R. K.; Misra, P.; Juluri, S.; Mamidi, N. V.; Rajagopalan, R., (-)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)-DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. *J Med Chem* **2001**, 44, (16), 2675-8.
119. Martin, J. A.; Brooks, D. A.; Prieto, L.; Gonzalez, R.; Torrado, A.; Rojo, I.; Lopez de Uralde, B.; Lamas, C.; Ferritto, R.; Dolores Martin-Ortega, M.; Agejas, J.; Parra, F.; Rizzo, J. R.; Rhodes, G. A.; Robey, R. L.; Alt, C. A.; Wendel, S. R.; Zhang, T. Y.; Reifel-Miller, A.; Montrose-Rafizadeh, C.; Brozinick, J. T.; Hawkins, E.; Misener, E. A.; Briere, D. A.; Ardecky, R.; Fraser, J. D.; Warshawsky, A. M., 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents. *Bioorg Med Chem Lett* **2005**, 15, (1), 51-5.
120. Imoto, H.; Sugiyama, Y.; Kimura, H.; Momose, Y., Studies on non-thiazolidinedione antidiabetic agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents. *Chem Pharm Bull (Tokyo)* **2003**, 51, (2), 138-51.

121. Rubenstrunk, A.; Hanf, R.; Hum, D. W.; Fruchart, J. C.; Staels, B., Safety issues and prospects for future generations of PPAR modulators. *Biochim Biophys Acta* **2007**, 1771, (8), 1065-81.
122. Li, P. P.; Shan, S.; Chen, Y. T.; Ning, Z. Q.; Sun, S. J.; Liu, Q.; Lu, X. P.; Xie, M. Z.; Shen, Z. F., The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. *Br J Pharmacol* **2006**, 148, (5), 610-8.
123. Chakrabarti, R.; Misra, P.; Vikramadithyan, R. K.; Premkumar, M.; Hiriyani, J.; Datla, S. R.; Damarla, R. K.; Suresh, J.; Rajagopalan, R., Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. *Eur J Pharmacol* **2004**, 491, (2-3), 195-206.
124. Hu, X.; Feng, Y.; Shen, Y.; Zhao, X. F.; Yu, J. H.; Yang, Y. S.; Leng, Y., Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice. *Acta Pharmacol Sin* **2006**, 27, (10), 1346-52.
125. Younk, L. M.; Uhl, L.; Davis, S. N., Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. *Expert Opin Drug Metab Toxicol* **2011**, 7, (6), 753-63.
126. Jain, M. R.; Giri, S. R.; Trivedi, C.; Bhoi, B.; Rath, A.; Vanage, G.; Vyas, P.; Ranvir, R.; Patel, P. R., Saroglitazar, a novel PPAR α / γ agonist with predominant PPAR α activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. *Pharmacology Research & Perspectives* **2015**, 3, (3), n/a-n/a.
127. Berger, J.; Leibowitz, M. D.; Doebber, T. W.; Elbrecht, A.; Zhang, B.; Zhou, G.; Biswas, C.; Cullinan, C. A.; Hayes, N. S.; Li, Y.; Tanen, M.; Ventre, J.; Wu, M. S.; Berger, G. D.; Mosley, R.; Marquis, R.; Santini, C.; Sahoo, S. P.; Tolman, R. L.; Smith, R. G.; Moller, D. E., Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. *J Biol Chem* **1999**, 274, (10), 6718-25.
128. Santini, C.; Berger, G. D.; Han, W.; Mosley, R.; MacNaul, K.; Berger, J.; Doebber, T.; Wu, M.; Moller, D. E.; Tolman, R. L.; Sahoo, S. P., Phenylacetic acid derivatives as hPPAR agonists. *Bioorg Med Chem Lett* **2003**, 13, (7), 1277-80.
129. Shearer, B. G.; Patel, H. S.; Billin, A. N.; Way, J. M.; Winegar, D. A.; Lambert, M. H.; Xu, R. X.; Leesnitzer, L. M.; Merrihew, R. V.; Huet, S.; Willson, T. M., Discovery of a novel class of PPARdelta partial agonists. *Bioorg Med Chem Lett* **2008**, 18, (18), 5018-22.

130. Evans, K. A.; Shearer, B. G.; Wisnoski, D. D.; Shi, D.; Sparks, S. M.; Sternbach, D. D.; Winegar, D. A.; Billin, A. N.; Britt, C.; Way, J. M.; Epperly, A. H.; Leesnitzer, L. M.; Merrihew, R. V.; Xu, R. X.; Lambert, M. H.; Jin, J., Phenoxyacetic acids as PPARdelta partial agonists: synthesis, optimization, and in vivo efficacy. *Bioorg Med Chem Lett* **2011**, 21, (8), 2345-50.
131. Epple, R.; Azimioara, M.; Russo, R.; Bursulaya, B.; Tian, S. S.; Gerken, A.; Iskandar, M., 1,3,5-Trisubstituted aryls as highly selective PPARdelta agonists. *Bioorg Med Chem Lett* **2006**, 16, (11), 2969-73.
132. Epple, R.; Russo, R.; Azimioara, M.; Cow, C.; Xie, Y.; Wang, X.; Wityak, J.; Karanewsky, D.; Gerken, A.; Iskandar, M.; Saez, E.; Martin Seidel, H.; Tian, S. S., 3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: Part 1. *Bioorg Med Chem Lett* **2006**, 16, (16), 4376-80.
133. Epple, R.; Cow, C.; Xie, Y.; Azimioara, M.; Russo, R.; Wang, X.; Wityak, J.; Karanewsky, D. S.; Tuntland, T.; Nguyen-Tran, V. T.; Cuc Ngo, C.; Huang, D.; Saez, E.; Spalding, T.; Gerken, A.; Iskandar, M.; Seidel, H. M.; Tian, S. S., Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists. *J Med Chem* **2010**, 53, (1), 77-105.
134. Weigand, S.; Bischoff, H.; Dittrich-Wengenroth, E.; Heckroth, H.; Lang, D.; Vaupel, A.; Woltering, M., Minor structural modifications convert a selective PPARalpha agonist into a potent, highly selective PPARdelta agonist. *Bioorg Med Chem Lett* **2005**, 15, (20), 4619-23.
135. Wickens, P.; Zhang, C.; Ma, X.; Zhao, Q.; Amatruda, J.; Bullock, W.; Burns, M.; Cantin, L. D.; Chuang, C. Y.; Claus, T.; Dai, M.; Dela Cruz, F.; Dickson, D.; Ehrgott, F. J.; Fan, D.; Heald, S.; Hentemann, M.; Iwuagwu, C. I.; Johnson, J. S.; Kumarasinghe, E.; Ladner, D.; Lavoie, R.; Liang, S.; Livingston, J. N.; Lowe, D.; Magnuson, S.; Mannelly, G.; Mugge, I.; Ogutu, H.; Pleasic-Williams, S.; Schoenleber, R. W.; Shapiro, J.; Shelekhin, T.; Sweet, L.; Town, C.; Tsutsumi, M., Indanylacetic acids as PPAR-delta activator insulin sensitizers. *Bioorg Med Chem Lett* **2007**, 17, (15), 4369-73.
136. Bratton, L. D.; Filzen, G. F.; Geyer, A.; Hoffman, J. K.; Lu, G.; Pulaski, J.; Trivedi, B. K.; Unangst, P. C.; Xu, X., Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists. *Bioorg Med Chem Lett* **2007**, 17, (13), 3624-9.
137. Sauerberg, P.; Olsen, G. S.; Jeppesen, L.; Mogensen, J. P.; Pettersson, I.; Jeppesen, C. B.; Daugaard, J. R.; Galsgaard, E. D.; Ynddal, L.; Fleckner, J.; Panajotova, V.; Polivka, Z.; Pihera, P.; Havranek, M.; Wulff, E. M., Identification and synthesis of

- a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo. *J Med Chem* **2007**, 50, (7), 1495-503.
138. Luckhurst, C. A.; Stein, L. A.; Furber, M.; Webb, N.; Ratcliffe, M. J.; Allenby, G.; Botterell, S.; Tomlinson, W.; Martin, B.; Walding, A., Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARdelta agonists. *Bioorg Med Chem Lett* **2011**, 21, (1), 492-6.
139. Choi, Y. J.; Roberts, B. K.; Wang, X.; Geaney, J. C.; Naim, S.; Wojnoonski, K.; Karpf, D. B.; Krauss, R. M., Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia. *Atherosclerosis* **2012**, 220, (2), 470-6.
140. Shearer, B. G.; Billin, A. N., The next generation of PPAR drugs: do we have the tools to find them? *Biochim Biophys Acta* **2007**, 1771, (8), 1082-93.
141. Liu, K. G.; Lambert, M. H.; Leesnitzer, L. M.; Oliver, W., Jr.; Ott, R. J.; Plunket, K. D.; Stuart, L. W.; Brown, P. J.; Willson, T. M.; Sternbach, D. D., Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis. *Bioorg Med Chem Lett* **2001**, 11, (22), 2959-62.
142. Xu, Y.; Etgen, G. J.; Broderick, C. L.; Canada, E.; Gonzalez, I.; Lamar, J.; Montrose-Rafizadeh, C.; Oldham, B. A.; Osborne, J. J.; Xie, C.; Shi, Q.; Winneroski, L. L.; York, J.; Yumibe, N.; Zink, R.; Mantlo, N., Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile. *J Med Chem* **2006**, 49, (19), 5649-52.
143. Mogensen, J. P.; Jeppesen, L.; Bury, P. S.; Pettersson, I.; Fleckner, J.; Nehlin, J.; Frederiksen, K. S.; Albrechtsen, T.; Din, N.; Mortensen, S. B.; Svensson, L. A.; Wassermann, K.; Wulff, E. M.; Ynddal, L.; Sauerberg, P., Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template. *Bioorg Med Chem Lett* **2003**, 13, (2), 257-60.
144. Sznaidman, M. L.; Haffner, C. D.; Maloney, P. R.; Fivush, A.; Chao, E.; Goreham, D.; Sierra, M. L.; LeGrumelec, C.; Xu, H. E.; Montana, V. G.; Lambert, M. H.; Willson, T. M.; Oliver, W. R., Jr.; Sternbach, D. D., Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity. *Bioorg Med Chem Lett* **2003**, 13, (9), 1517-21.
145. Kasuga, J.; Oyama, T.; Hirakawa, Y.; Makishima, M.; Morikawa, K.; Hashimoto, Y.; Miyachi, H., Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part. *Bioorg Med Chem Lett* **2008**, 18, (16), 4525-8.

146. Artis, D. R.; Lin, J. J.; Zhang, C.; Wang, W.; Mehra, U.; Perreault, M.; Erbe, D.; Krupka, H. I.; England, B. P.; Arnold, J.; Plotnikov, A. N.; Marimuthu, A.; Nguyen, H.; Will, S.; Signaevsky, M.; Kral, J.; Cantwell, J.; Settachatgull, C.; Yan, D. S.; Fong, D.; Oh, A.; Shi, S.; Womack, P.; Powell, B.; Habets, G.; West, B. L.; Zhang, K. Y.; Milburn, M. V.; Vlasuk, G. P.; Hirth, K. P.; Nolop, K.; Bollag, G.; Ibrahim, P. N.; Tobin, J. F., Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. *Proc Natl Acad Sci U S A* **2009**, 106, (1), 262-7.
147. Oberfield, J. L.; Collins, J. L.; Holmes, C. P.; Goreham, D. M.; Cooper, J. P.; Cobb, J. E.; Lenhard, J. M.; Hull-Ryde, E. A.; Mohr, C. P.; Blanchard, S. G.; Parks, D. J.; Moore, L. B.; Lehmann, J. M.; Plunket, K.; Miller, A. B.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M., A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. *Proc Natl Acad Sci U S A* **1999**, 96, (11), 6102-6.
148. Minoura, H.; Takeshita, S.; Ita, M.; Hirosumi, J.; Mabuchi, M.; Kawamura, I.; Nakajima, S.; Nakayama, O.; Kayakiri, H.; Oku, T.; Ohkubo-Suzuki, A.; Fukagawa, M.; Kojo, H.; Hanioka, K.; Yamasaki, N.; Imoto, T.; Kobayashi, Y.; Mutoh, S., Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. *Eur J Pharmacol* **2004**, 494, (2-3), 273-81.
149. Burgermeister, E.; Schnoebelen, A.; Flament, A.; Benz, J.; Stihle, M.; Gsell, B.; Rufer, A.; Ruf, A.; Kuhn, B.; Marki, H. P.; Mizrahi, J.; Sebokova, E.; Niesor, E.; Meyer, M., A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. *Mol Endocrinol* **2006**, 20, (4), 809-30.
150. Misra, P.; Chakrabarti, R.; Vikramadithyan, R. K.; Bolusu, G.; Juluri, S.; Hiriyani, J.; Gershome, C.; Rajjak, A.; Kashireddy, P.; Yu, S.; Surapureddi, S.; Qi, C.; Zhu, Y. J.; Rao, M. S.; Reddy, J. K.; Ramanujam, R., PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. *J Pharmacol Exp Ther* **2003**, 306, (2), 763-71.
151. Berger, J. P.; Petro, A. E.; Macnaul, K. L.; Kelly, L. J.; Zhang, B. B.; Richards, K.; Elbrecht, A.; Johnson, B. A.; Zhou, G.; Doebber, T. W.; Biswas, C.; Parikh, M.; Sharma, N.; Tanen, M. R.; Thompson, G. M.; Ventre, J.; Adams, A. D.; Mosley, R.; Surwit, R. S.; Moller, D. E., Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. *Mol Endocrinol* **2003**, 17, (4), 662-76.
152. Acton, J. J., 3rd; Akiyama, T. E.; Chang, C. H.; Colwell, L.; Debenham, S.; Doebber, T.; Einstein, M.; Liu, K.; McCann, M. E.; Moller, D. E.; Muise, E. S.; Tan, Y.;

- Thompson, J. R.; Wong, K. K.; Wu, M.; Xu, L.; Meinke, P. T.; Berger, J. P.; Wood, H. B., Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume. *J Med Chem* **2009**, 52, (13), 3846-54.
153. Taygerly, J. P.; McGee, L. R.; Rubenstein, S. M.; Houze, J. B.; Cushing, T. D.; Li, Y.; Motani, A.; Chen, J. L.; Frankmoelle, W.; Ye, G.; Learned, M. R.; Jaen, J.; Miao, S.; Timmermans, P. B.; Thoolen, M.; Kearney, P.; Flygare, J.; Beckmann, H.; Weiszmann, J.; Lindstrom, M.; Walker, N.; Liu, J.; Biermann, D.; Wang, Z.; Hagiwara, A.; Iida, T.; Aramaki, H.; Kitao, Y.; Shinkai, H.; Furukawa, N.; Nishiu, J.; Nakamura, M., Discovery of INT131: a selective PPARgamma modulator that enhances insulin sensitivity. *Bioorg Med Chem* **2013**, 21, (4), 979-92.
154. Yamazaki, Y.; Abe, K.; Toma, T.; Nishikawa, M.; Ozawa, H.; Okuda, A.; Araki, T.; Oda, S.; Inoue, K.; Shibuya, K.; Staels, B.; Fruchart, J. C., Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. *Bioorg Med Chem Lett* **2007**, 17, (16), 4689-93.
155. Fruchart, J. C., Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. *Cardiovasc Diabetol* **2013**, 12, 82.
156. Rau, O.; Zettl, H.; Popescu, L.; Steinhilber, D.; Schubert-Zsilavecz, M., The treatment of dyslipidemia--what's left in the pipeline? *ChemMedChem* **2008**, 3, (2), 206-21.
157. Pingali, H.; Jain, M.; Shah, S.; Basu, S.; Makadia, P.; Goswami, A.; Zaware, P.; Patil, P.; Godha, A.; Giri, S.; Goel, A.; Patel, M.; Patel, H.; Patel, P., Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. *Bioorg Med Chem Lett* **2008**, 18, (20), 5586-90.
158. Pingali, H.; Jain, M.; Shah, S.; Makadia, P.; Zaware, P.; Goel, A.; Patel, M.; Giri, S.; Patel, H.; Patel, P., Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists. *Bioorg Med Chem* **2008**, 16, (15), 7117-27.
159. Pingali, H.; Jain, M.; Shah, S.; Makadia, P.; Zaware, P.; Jamili, J.; Sairam, K. V. V. M.; Patil, P.; Suthar, D.; Giri, S.; Patel, H.; Patel, P., Design and synthesis of novel 1, 3-dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists. *Letters in Drug Design and Discovery* **2010**, 7, (6), 421-429.

160. Pingali, H.; Jain, M.; Shah, S.; Patil, P.; Makadia, P.; Zaware, P.; Sairam, K. V.; Jamili, J.; Goel, A.; Patel, M.; Patel, P., Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. *Bioorg Med Chem Lett* **2008**, 18, (24), 6471-5.
161. Pingali, H.; Jain, M.; Shah, S.; Zaware, P.; Makadia, P.; Pola, S.; Thube, B.; Patel, D.; Patil, P.; Priyadarshini, P.; Suthar, D.; Shah, M.; Giri, S.; Patel, P., Design and synthesis of novel bis-oximinoalkanoic acids as potent PPAR alpha agonists. *Bioorg Med Chem Lett* **2010**, 20, (3), 1156-61.
162. Casimiro-Garcia, A.; Bigge, C. F.; Davis, J. A.; Padalino, T.; Pulaski, J.; Ohren, J. F.; McConnell, P.; Kane, C. D.; Royer, L. J.; Stevens, K. A.; Auerbach, B. J.; Collard, W. T.; McGregor, C.; Fakhoury, S. A.; Schaum, R. P.; Zhou, H., Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies. *Bioorg Med Chem* **2008**, 16, (9), 4883-907.
163. Liu, W.; Liu, K.; Wood, H. B.; McCann, M. E.; Doebber, T. W.; Chang, C. H.; Akiyama, T. E.; Einstein, M.; Berger, J. P.; Meinke, P. T., Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia. *J Med Chem* **2009**, 52, (14), 4443-53.
164. Suh, Y. G.; Kim, N. J.; Koo, B. W.; Lee, K. O.; Moon, S. H.; Shin, D. H.; Jung, J. W.; Paek, S. M.; Chang, D. J.; Li, F.; Kang, H. J.; Le, T. V.; Chae, Y. N.; Shin, C. Y.; Kim, M. K.; Lim, J. I.; Ryu, J. S.; Park, H. J., Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. *J Med Chem* **2008**, 51, (20), 6318-33.
165. Yanagisawa, H.; Takamura, M.; Yamada, E.; Fujita, S.; Fujiwara, T.; Yachi, M.; Isobe, A.; Hagiwara, Y., Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship. *Bioorg Med Chem Lett* **2000**, 10, (4), 373-5.
166. Pingali, H.; Raval, S.; Raval, P.; Makadia, P.; Zaware, P.; Goel, A.; Suthar, D.; Jain, M.; Patel, P., Novel oxazole containing phenylpropane derivatives as peroxisome proliferator activated receptor agonists with hypolipidemic activity. *Pharmazie* **2008**, 63, (7), 497-502.
167. Zaware, P.; Shah, S. R.; Pingali, H.; Makadia, P.; Thube, B.; Pola, S.; Patel, D.; Priyadarshini, P.; Suthar, D.; Shah, M.; Jamili, J.; Sairam, K. V.; Giri, S.; Patel, L.; Patel, H.; Sudani, H.; Jain, M.; Patel, P.; Bahekar, R., Modulation of PPAR subtype

- selectivity. Part 2: Transforming PPARalpha/gamma dual agonist into alpha selective PPAR agonist through bioisosteric modification. *Bioorg Med Chem Lett* **2011**, 21, (2), 628-32.
168. Makadia, P.; Shah, S. R.; Pingali, H.; Zaware, P.; Patel, D.; Pola, S.; Thube, B.; Priyadarshini, P.; Suthar, D.; Shah, M.; Giri, S.; Trivedi, C.; Jain, M.; Patel, P.; Bahekar, R., Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists. *Bioorg Med Chem* **2011**, 19, (2), 771-82.